Infectious diseases are one of the largest threats to global public health. The focus on the threat has never been greater, with the COVID-19 pandemic demonstrating the critical need for a more proactive approach within governments, biopharma, and investment communities to overcome the pressing issues in anti-infective drug development to combat antimicrobial resistance.
With some now considering the field as the new ‘Wall Street darling’, especially given the $1 billion launch of the AMR action fund, the Digital Anti-Infectives Drug Development Summit has arrived as the most comprehensive and industry-dedicated forum that addresses the biggest challenges in the development and commercialization of anti-infective drugs.
Bringing together 60+ senior leaders from large pharma, innovative biotech, academia and investment companies, join us this April to discuss data-driven and solution-based approaches that focus on developing high value clinical candidates, novel modalities and effective strategies, that address market sustainability and aim for superiority.
More information available here
Please contact us (contact@beam-alliance.eu) to benefit from a VIP code to retrieve 10% off registration fee for BEAM Members only!